The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa

Autor: Yüksel Totan, Aslihan Yüce, Emre Güler, Mehmet Serdar Dervişoğulları
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Time Factors
Visual acuity
genetic structures
Visual Acuity
Retinal Pigment Epithelium
Audiology
0302 clinical medicine
lcsh:Ophthalmology
Medicine
Enzyme Inhibitors
Valproic Acid
medicine.diagnostic_test
Middle Aged
Electroretinogram
Visual field
Dose–response relationship
Original Article
Female
lipids (amino acids
peptides
and proteins)
medicine.symptom
Erg
Tomography
Optical Coherence
Retinitis Pigmentosa
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Visual Field
Ophthalmoscopy
Young Adult
03 medical and health sciences
Ophthalmology
Retinitis pigmentosa
Electroretinography
Humans
Adverse effect
Dose-Response Relationship
Drug
business.industry
medicine.disease
eye diseases
030104 developmental biology
lcsh:RE1-994
030221 ophthalmology & optometry
Visual Field Tests
sense organs
Visual Fields
business
Follow-Up Studies
Zdroj: Indian Journal of Ophthalmology
Indian Journal of Ophthalmology, Vol 65, Iss 10, Pp 984-988 (2017)
Popis: WOS: 000413741300015 PubMed ID: 29044065 Purpose: To evaluate the efficacy and safety of valproic acid (VPA) treatment in patients with retinitis pigmentosa (RP). Methods: A total of 48 eyes of 24 patients (13 males, 11 females) with RP prescribed VPA were included. The length of VPA treatment was 6-12 months (mean 9.4 months). Parameters evaluated were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution [logMAR]), visual field analyses (VFAs) with Humprey automated perimetry, multifocal electroretinography (ERG) with Roland-RETI scan, and VPA side effects. Results: Mean age was 34.3 +/- 10.3 years (range 18-56 years). Fifteen of the patients (30 eyes) had two ERG and VFA tracings, allowing comparison between baseline and follow-up (range 6-12 months). Mean BCVA before and after VPA therapy was 0.36 +/- 0.38 and 0.36 +/- 0.37 logMAR, respectively (P = 0.32). Quantitative perimetric indices including mean deviation and pattern standard deviation were not significantly changed after VPA therapy (P > 0.05). P1 amplitudes (in terms of nV/deg(2) and mV) of ERG waves were significantly decreased in the rings 1, 3, and 4 after VPA therapy (P < 0.05). Regarding the N1 amplitudes, the only significant decrease was observed in area 1 (P = 0.03). In addition, N1 latency was significantly increased in area 3 after VPA therapy (P = 0.04). Conclusions: VPA therapy did not have any significant benefit on BCVA and VFA. In addition, it may be associated with decline in some ERG parameters. Therefore, physicians should avoid prescribing VPA for RP until its safety and efficacy are appropriately evaluated.
Databáze: OpenAIRE
Externí odkaz: